Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Previous studies suggested that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may initially worsen and possibly increase the risk of diabetic retinopathy. However, data on this possible association remain limited. Thus, this population-based study aimed to determine whether use of GLP-1 RAs is associated with an increased risk of incident diabetic retinopathy. RESEARCH DESIGN AND METHODS: Using the U.K. Clinical Practice Research Datalink (CPRD), we conducted a cohort study among 77,115 patients with type 2 diabetes initiating antidiabetic drugs between January 2007 and September 2015. Adjusted hazard ratios (HRs) and 95% CIs of incident diabetic retinopathy were estimated using time-dependent Cox proportional hazards models, comparing use of GLP-1 RAs with current use of two or more oral antidiabetic drugs. In an ancillary analysis, new users of GLP-1 RAs were compared with new users of insulin. RESULTS: During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with current use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy overall (HR 1.00, 95% CI 0.85–1.17). Compared with insulin, GLP-1 RAs were associated with a decreased risk of diabetic retinopathy (HR 0.67, 95% CI 0.51–0.90). CONCLUSIONS: The associations with diabetic retinopathy varied according to the type of comparator. When compared with use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy. The apparent lower risk of diabetic retinopathy associated with GLP-1 RAs compared with insulin may be due to residual confounding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several large real‐world studies have examined the association between GLP‐1RA and retinopathy, with apparently conflicting results in three recent large cohort studies, 115 , 118 , 119 leaving the question unsettled.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [118]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“We repeated the analyses to account for competing risk due to deaths from any cause (21).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationFlexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“prevalent users (34), because all patients entering the base and study cohorts were required to be new users of antidiabetic drugs.”
Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583 · cited 1×
“Exposures To further assess the validity of our findings, we conducted two additional analyses using negative and positive control exposures (24).”
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109 · cited 2×
“The linkage of the CPRD to the HES is possible from 1 April 1997 onward and is limited to general practices in England that have consented to the linkage scheme (currently representing 75% of all practices in England) (13).”
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Sensitivity Analysis Without Assumptions
Ding, P., & VanderWeele, T. J. (2016) · Epidemiology · doi:10.1097/ede.0000000000000457 · Cited by 570
Younis, N., Broadbent, D. M., Vora, J. P., & Harding, S. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12267-2 · Cited by 289
Hernández, C., Bogdanov, P., Corraliza, L., García-Ramírez, M., Solà-Adell, C., Arranz, J. A., Arroba, A. I., Valverde, A. M., & Simó, R. (2016) · Diabetes · doi:10.2337/db15-0443 · Cited by 267
Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research
Yola, M., & Lucien, A. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90170-8 · Cited by 253
HIV-ASSOCIATED RETINOPATHY IN THE HAART ERA
GOLDBERG, D. E., Smithen, L., Angelilli, A., & Freeman, W. R. (2005) · Retina · doi:10.1097/00006982-200507000-00015 · Cited by 144
Thomas, R. L., Dunstan, F., Luzio, S. D., Roy Chowdury, S., Hale, S. L., North, R. V., Gibbins, R. L., & Owens, D. R. (2012) · BMJ · doi:10.1136/bmj.e874 · Cited by 142
Faillie, J.-L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1531 · Cited by 134
Self-citationEffect of an Insulin-induced Decrease in Blood Glucose on the Human Diabetic Retinal Circulation
Grunwald, J. E., Riva, C. E., Martin, D. B., Quint, A., & Epstein, P. A. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33257-9 · Cited by 118
Role of disease risk scores in comparative effectiveness research with emerging therapies
Glynn, R. J., Gagne, J. J., & Schneeweiß, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3231 · Cited by 116
Makri, Ο. E., Georgalas, I., & Georgakopoulos, C. D. (2013) · Drugs · doi:10.1007/s40265-013-0055-x · Cited by 59
Five-Year Efficacy and Safety Data of Exenatide Once Weekly
Wysham, C., MacConell, L., Maggs, D. G., Zhou, M., Griffin, P. S., & TRAUTMANN, M. E. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.008 · Cited by 57
The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
Varadhan, L., Humphreys, T., Walker, A. B., & Varughese, G. I. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.041 · Cited by 49
Progression of Retinopathy in Insulin-Treated Type 2 Diabetic Patients
Henricsson, M., Berntorp, K. E., Fernlund, P., & Sundkvist, G. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.381 · Cited by 48
GLP-1 agonist treatment: Implications for diabetic retinopathy screening
Varadhan, L., Humphreys, T., Hariman, C., Walker, A. B., & Varughese, G. I. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.08.017 · Cited by 47
The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?
Gorman, D. M., le Roux, C. W., & Docherty, N. G. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.354 · Cited by 41
Kumamaru, H., Gagne, J. J., Glynn, R. J., Setoguchi, S., & Schneeweiß, S. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.02.011 · Cited by 29
Physician perceptions of GLP-1 receptor agonists in the UK
Matza, L. S., Curtis, S. E., Jordan, J. B., Adetunji, O., Martin, S. A., & Boye, K. S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1147025 · Cited by 28
Brooks, A. M., & Lissett, C. A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02650.x · Cited by 24
The NHS diabetic eye screening programme
Peate, I. (2019) · British Journal of Healthcare Assistants · doi:10.12968/bjha.2019.13.12.596 · Cited by 23
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Microvascular complications in diabetes: A growing concern for cardiologists
Avogaro, A., & Fadini, G. P. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.030 · Cited by 160
Gaborit, B., Julla, J.-B., Besbes, S., Proust, M., Vincentelli, C., Alos, B., Ancel, P., Alzaid, F., Garcia, R., Mailly, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz069 · Cited by 95
Ponirakis, G., Abdul‐Ghani, M. A., Jayyousi, A., Almuhannadi, H., Petropoulos, I. N., Khan, A., Gad, H., Migahid, O., Megahed, A., DeFronzo, R. A., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001420 · Cited by 83
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02753-6 · Cited by 74
Metadata
- Authors
- Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L.
- Affiliations
- Jewish General Hospital (CA)
- University of British Columbia (CA)
- University of Toronto (CA)
- Corresponding author
- Azoulay, Laurent
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-27
- Volume
- 41
- Issue
- 11
- Pages
- 2330-2338
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2889059090
- Cited by
- 70
- References
- 35
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 12 · 2023: 14 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 1
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Canada
- McGill University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, diabetic retinopathy, type 2 diabetes, insulin, oral antidiabetic drugs, residual confounding, antidiabetic drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Risk Factors, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.